- Home
- MNKD vs ADPT Comparison
MNKD vs ADPT Comparison
Compare MNKD & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNKD
- ADPT
- Stock Information
- Founded
- MNKD 1991
- ADPT 2009
- Country
- MNKD United States
- ADPT United States
- Employees
- MNKD N/A
- ADPT N/A
- Industry
- MNKD Biotechnology: Pharmaceutical Preparations
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MNKD Health Care
- ADPT Health Care
- Exchange
- MNKD Nasdaq
- ADPT Nasdaq
- Market Cap
- MNKD 1.7B
- ADPT 2.0B
- IPO Year
- MNKD 2004
- ADPT 2019
- Fundamental
- Price
- MNKD $5.72
- ADPT $14.40
- Analyst Decision
- MNKD Strong Buy
- ADPT Strong Buy
- Analyst Count
- MNKD 5
- ADPT 9
- Target Price
- MNKD $10.80
- ADPT $13.22
- AVG Volume (30 Days)
- MNKD 3.8M
- ADPT 2.1M
- Earning Date
- MNKD 11-06-2025
- ADPT 11-06-2025
- Dividend Yield
- MNKD N/A
- ADPT N/A
- EPS Growth
- MNKD 149.32
- ADPT N/A
- EPS
- MNKD 0.11
- ADPT N/A
- Revenue
- MNKD $301,736,000.00
- ADPT $205,216,000.00
- Revenue This Year
- MNKD $16.36
- ADPT $32.76
- Revenue Next Year
- MNKD $20.34
- ADPT $15.81
- P/E Ratio
- MNKD $52.68
- ADPT N/A
- Revenue Growth
- MNKD 21.48
- ADPT 21.60
- 52 Week Low
- MNKD $3.38
- ADPT $4.27
- 52 Week High
- MNKD $7.63
- ADPT $15.26
- Technical
- Relative Strength Index (RSI)
- MNKD 63.58
- ADPT 60.53
- Support Level
- MNKD $5.33
- ADPT $14.04
- Resistance Level
- MNKD $5.90
- ADPT $15.26
- Average True Range (ATR)
- MNKD 0.21
- ADPT 0.73
- MACD
- MNKD -0.02
- ADPT 0.05
- Stochastic Oscillator
- MNKD 77.46
- ADPT 69.09
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).